Dr. Zeinab I. El Boghdadly, MD

Dr. El Boghdadly practices at Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center.

Dr. El Boghdadly's NPI, 1699046466, was assigned on January 25, 2012. Dr. El Boghdadly holds Ohio license 35128659.

Dr. El Boghdadly's primary practice is Ohio State University Hospital, at 410 West 10th Avenue, Columbus, OH 43210 in Franklin County. The practice phone is (614) 293-9700.

Dr. El Boghdadly's primary practice is Ohio State University Hospital in Columbus, Ohio, part of The Ohio State University Wexner Medical Center. Dr. El Boghdadly is also affiliated with The James Cancer Hospital and Solove Research Institute. The medical group on file is Atrium Health Cleveland Imaging. Dmand AI also links Dr. El Boghdadly to 1 more hospital, 2 hospital outpatient departments, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. El Boghdadly practices, 6 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. El Boghdadly's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. El Boghdadly is licensed in Ohio.

CMS data shows 329 Medicare services from Dr. El Boghdadly across 4 procedure codes in 2024, for 184 Medicare patients. Medicare paid $30,715 for them.

CMS counts 184 Medicare patients who saw Dr. El Boghdadly in 2024. The largest group is 65 to 74, with 99 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 16% are also on Medicaid. Their average risk score is 3.44, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. El Boghdadly's median patient age at 65, with 39% women.

In 2024, Dr. El Boghdadly wrote 222 Medicare Part D claims for 46 patients. 82% of them were for generic drugs. CMS names the drug for 133 of them, across 9 drugs with 11 or more claims each, at $74,562 in total drug cost. In 2023, CMS named 39 claims across 3 drugs.

Dr. El Boghdadly accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. El Boghdadly as offering telehealth.

Dmand AI links 11 papers to Dr. El Boghdadly, published from 2019 to 2025. 2020 was the busiest year, with 2. The most frequent topics are Anti-Bacterial Agents, Hematologic Neoplasms and Bacteremia. Dr. El Boghdadly has published most often in Blood Adv. Dr. El Boghdadly's most frequent co-authors are Roy F. Chemaly, MD, Marcie L. Riches, MD and Leslie A. Andritsos, MD.

CMS Open Payments shows 6 general payments to Dr. El Boghdadly from 2 drug and device companies in 2016. Food and beverage make up the largest share, 100% of the total. Astellas Pharma US Inc paid the most, $89.